The first generation of antibody-based inhibitory IC enables to restore a correct immune response towards tumor cells, includes antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA4), programmed cell death (PD-1), and programmed cell death ligands (PD-L1/PD-L2). This evidence concerns the gene CTLA4 and neoplasm.